share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh

SEC ·  Jun 1 04:20

Summary by Futu AI

In a recent transaction, Sandesh Mahatme, associated with CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The specific details regarding the number of shares involved, the nature of the shares, the transaction price, and the post-transaction holdings were not disclosed in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
In a recent transaction, Sandesh Mahatme, associated with CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The specific details regarding the number of shares involved, the nature of the shares, the transaction price, and the post-transaction holdings were not disclosed in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.